33 Blood-based tumor mutation burden (bTMB) predicts response to immune checkpoint blockade-based combination therapy (ICBC) in advanced non-small cell lung cancer (NSCLC): a real-world (RW) analysis

33 Blood-based tumor mutation burden (bTMB) predicts response to immune checkpoint blockade-based combination therapy (ICBC) in advanced non-small cell lung cancer (NSCLC): a real-world (RW) analysis

Bibliographic Details
Main Authors: Nicole Zhang, Leylah Drusbosky, Jiemin Liao, Bruna Pellini, Sean Gordon, Reagan Barnett, Katie Quinn, Sara Wienke, Martina Lefterova, Lauren Lawrence, Lesli Kiedrowski, Ross Eppler, Justin Odegaard, Han-Yu Chuang
Format: Article
Language:English
Published: BMJ Publishing Group 2023-11-01
Series:Journal for ImmunoTherapy of Cancer

Similar Items